Form 4: Corbus Pharmaceuticals CFO Sean Moran Reports Stock Option Exercises and Sales
SEC Form 4
Sean Moran, CFO of Corbus Pharmaceuticals, reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Sean Moran, the Chief Financial Officer of Corbus Pharmaceuticals Holdings, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- On June 14, 2024, Mr. Moran exercised options to purchase common stock at strike prices of $30 and $4.26, acquiring 1,567 and 7,788 shares respectively.
- He then sold 1,567 shares at a weighted average price of $49.8738 and 7,788 shares at a weighted average price of $49.8738 on the same day.
- On June 17, 2024, Mr. Moran exercised options to purchase 6,730 shares at a strike price of $14.10 and sold them at a weighted average price of $46.774.
- On June 18, 2024, Mr. Moran exercised options to purchase 1,958 shares at a strike price of $30 and sold them at a weighted average price of $42.1242.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 15, 2024.
- Following these transactions, Mr. Moran directly owns 48,605 shares of Corbus Pharmaceuticals common stock, which includes 40,176 restricted stock units (RSUs) vesting over four years starting February 12, 2025.
- He also holds options to purchase additional shares at various exercise prices.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment or misalignment of interests between management and shareholders.
Stakeholder Impact
- Shareholders may be interested in the CFO's transactions as an indicator of management's confidence in the company.
- The transactions themselves are unlikely to have a significant impact on other stakeholders.
Key Dates
| Date | Description |
|---|---|
| 02/01/2023 | 25% of options vested related to the annual option award made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. |
| 03/02/2023 | Commencement of the remaining 75% of options vesting in equal monthly installments related to the annual option award made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. |
| 02/13/2024 | 25% of options vested related to the annual option award made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. |
| 03/13/2024 | Commencement of the remaining 75% of options vesting in equal monthly installments related to the annual option award made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. |
| 03/15/2024 | Date the Reporting Person adopted a Rule 10b5-1 trading plan. |
| 06/14/2024 | Date of multiple transactions involving the exercise of options and sale of common stock. |
| 06/17/2024 | Date of multiple transactions involving the exercise of options and sale of common stock. |
| 06/18/2024 | Date of multiple transactions involving the exercise of options and sale of common stock. |
| 10/22/2024 | Expiration date of options to purchase common stock. |
| 02/12/2025 | First vesting date for 25% of restricted stock units (RSUs). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.